Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-03-25
2008-03-25
Paras, Jr., Peter (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A
Reexamination Certificate
active
07347998
ABSTRACT:
A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.
REFERENCES:
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5512421 (1996-04-01), Burns et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5643770 (1997-07-01), Mason et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5710022 (1998-01-01), Zhu et al.
patent: 5800811 (1998-09-01), Hall et al.
patent: 5821234 (1998-10-01), Dzau
patent: 5985655 (1999-11-01), Anderson et al.
patent: 6004798 (1999-12-01), Anderson et al.
patent: 6864082 (2005-03-01), Hall et al.
patent: 2002/0173538 (2002-11-01), Shiao
patent: 334301 (1989-02-01), None
patent: WO 92/06180 (1992-04-01), None
patent: WO 93/00103 (1993-01-01), None
patent: WO 93/09221 (1993-05-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 93/25234 (1993-12-01), None
patent: WO 94/06920 (1994-03-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/11524 (1994-05-01), None
patent: WO 94/12626 (1994-06-01), None
patent: WO 94/27643 (1994-12-01), None
patent: WO 96/30504 (1996-03-01), None
patent: WO 96/23882 (1996-08-01), None
patent: WO 96/31602 (1996-10-01), None
patent: WO02/18572 (2002-03-01), None
Galanis, E et al. Crit Rev Oncol Hematol 38(3):177-192, 2001.
Scanlon, KJ Curr Pharm Biotech 5:415-420, 2004.
Lenz, HJ et al. Human Gene Therapy 12:1515-1537, 2002.
Guantam, A et al. Am J Respir Med 1(1):35-46, 2002.
Yang, X Radiology 228:36-49, 2003.
Tomasoni, S and A Benigni. Current Gene Therapy 4(1):115-122, 2004.
Barinaga,Science, vol. 266, pp. 1326 (Nov. 1994).
Defer, et al.,J. Virology, vol. 64, pp. 3661-3673 (1990).
Hall, et al.,Human Gene Therapy, vol. 8, pp. 2183-2192 (1990).
Kasahara, et al.,Science, vol. 266, pp. 1373-1376 (Nov. 1994).
Kozak, et al.,J. Virol., vol. 64, No. 7, pp. 3500-3508 (Jul. 1990).
Neda, et al.,J. Biol. Chem.., vol. 266, No. 22, pp. 14143-14146 (1991).
Salmons, et al.,Human Gene Therapy, vol. 4, pp. 129-141 (1993).
Valsesia-Wittman, et al.,J. Virol., vol. 70, No. 3, pp. 2059-2064 (Mar. 1996).
Xie, et al.,J. Biol. Chem., vol. 271, No. 14, pp. 8121-8125 (Apr. 1996).
Behrens, et al. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci. 2002;43(4):968-77.
Chu, et al. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther. 1994;1(5):292-9.
Cripps, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clinical Cancer Research. 2002; 8:2188-2192.
Gordon, et al. First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol. 2004;24(1):177-85.
Gordon, et al. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res. 2000;60(13):3343-7.
Gordon, et al. Lesion-targeted injectable vectors for vascular restenosis. Hum Gene Ther. 2001;12(10):1277-87.
Gordon, et al. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther. 2001;12(2):193-204.
Guibinga, et al. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther. 2004;9(1):76-84.
Hall, et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther. 2000;11(7):983-93.
Hall, et al. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther. 1997;8(18):2183-92.
Jones, et al. Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Advanced Drug Delivery Reviews. 1998; 31:153-170.
Marshall, et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 2004; 4:268-274.
Oza, et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecological Oncology. 2003; 89:129-133.
Skotzko, et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Research. 1995; 55:5493-5498.
Soneoka, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23(4):628-33.
Tolcher, et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clinical Cancer Research. 2002; 8: 2530-2535.
Williams, et al. Identification of a novel cyclin-like protein in human tumor cells. Journal of Biological Chemistry. 1993; 268:8871-8880.
Xu, et al. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med. 2001;8(1):19-30.
Gordon, et al. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol. 2007; 30(6):1297-307.
Gordon, et al. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. Int J Oncol. 2006; 29(5):1053-64.
Song, et al. Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring. Hum Gene Ther. 2003; 14(3):306-9.
Gordon Erlinda Maria
Hall Frederick L.
Noble Marcia S.
Paras, Jr. Peter
University of Southern California
Wilson Sonsini Goodrich & Rosati
LandOfFree
Method of delivering therapeutic agents to site of tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of delivering therapeutic agents to site of tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of delivering therapeutic agents to site of tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799543